Cigna Corp (CI)

Investment Committee Summary

Investment Thesis

At $280 (25 August 2026) Cigna trades at roughly 9x forward earnings, a wide discount to the managed-care peer median. The market is pricing a payer whose pharmacy-benefit-heavy earnings mix is permanently exposed to reform, and paying almost nothing for growth. The engine broadly agrees rather than dissents. Probability-weighted value is $273, the cash-flow anchor reads lower still, and the blend triangulates to $266 — a gap of -5% that leaves the shares fairly valued against the anchor set. Medical-cost variance, not membership growth, dominates the distribution, and a consolidated operating margin of 3.6% on an enormous revenue base means small movements in the medical-loss ratio swing earnings hard. The structural scenario, whose target sits below the 52-week low, caps what the cheap headline multiple is actually worth, and net debt of ~$23.9B ranks ahead of the equity. HOLD follows: the discount to peers is real, but it is compensation for medical-cost and policy risk rather than evidence of mispricing. The single most damaging risk is federal pharmacy-benefit legislation that delinks rebates or bans spread pricing.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($280) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The steelman bear is legislative, not cyclical. Cigna's earnings now lean on Evernorth's pharmacy-benefit economics — rebate retention, spread pricing and specialty dispensing — precisely the practices legislators in both parties have drafted bills to dismantle. If delinking or a commercial spread-pricing ban is enacted, the consequence is not one weak quarter but a permanent repricing of the model, while the residual health-benefits book simultaneously absorbs elevated medical-cost trend against an operating margin of 3.6% that leaves no buffer at all. Earnings settle materially lower and the market applies a multiple well beneath 9x to a business it now treats as a regulated utility carrying litigation overhang. That compounds to the structural target below the 52-week low. The low headline multiple offers no protection on the way down when the earnings base itself is what is being legislated.

Key Debate

Gross Margin explains 68% of Monte Carlo outcome variance — the single variable that decides which side is right.

What the Market Is Pricing In

At the current price, the market pays 9.2× consensus forward EPS, vs the house DCF terminal 8.0×, and a peer median 14.8×. The house DCF sits 2% below spot, so the market is pricing in more than the house case — roughly 0.2pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily growth-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Medicare/Medicaid Reform / MLR Squeeze' downside ($120) to a 'Bull — Margin Recovery / Re-Rate' bull case ($484); the probability-weighted blend (PWEV $273) is -3% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — free cash flow net of SBC is $8.39B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Medicare/Medicaid Reform / MLR Squeeze (20%, $120). Structural impairment — Medicare/Medicaid reform / MLR squeeze: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Cost-Trend Spike / Rate Inadequacy (17%, $204). Cyclical downturn — membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy weakens for 1–2 years before normalising.
• Base — Membership + Premium Growth (35%, $282). Mid-cycle — normalised membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy; disciplined capital allocation; steady returns.
• Growth — MA / Care-Services (Optum-style) (20%, $381). Upside — MA + care-services growth lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Margin Recovery / Re-Rate (8%, $484). Upside tail — sustained tight conditions or a structural re-rate on MA + care-services growth.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $239 and 40% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (68% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 8.0x terminal FCF multiple → $274. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $1,936; the peer-median forward P/E is 14.8x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 620% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Managed Care / Health Services multiple (AI re-rating) (base 9.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 15.3× (simple median 14.8×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $236–$332, centre $279 (-0% vs spot); spot sits at the 47th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Margin Recovery / Re-Rate): $484.

Company Overview & Business Model

Cigna Corp — HEALTHCARE · HEALTHCARE PLANS. Cigna is an American multinational managed healthcare and insurance company based in Bloomfield, Connecticut. Its insurance subsidiaries are major providers of medical, dental, disability, life and accident insurance and related products and services, the majority of which are offered through employers and other groups (e.g. governmental and non-governmental organizations, unions and associations).

How it makes money.

Edge. Narrow moat — Cigna's moat is scale in PBM (Express Scripts) and integrated pharmacy/medical data, a narrow moat rather than wide because that scale is precisely what draws reform. At ~9x forward the market already assigns almost no moat premium; the falsifiable test is PBM spread economics: if reform caps rebate retention or mandates pass-through, the terminal multiple stays at a reform-discounted low-double-digit level rather than re-rating to the ~14-15x payer median.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 153% — cash-backed.

Competitive Moat

Moat sources:

• FACT: Express Scripts is one of three PBMs controlling the large majority of U.S. pharmacy claims; genuine scale in formulary and rebate negotiation
• INFERENCE: integrated medical + pharmacy + specialty (Accredo) data creates cross-sell and cost-management advantage vs standalone payers
• FACT: large employer/commercial book with sticky multi-year ASO relationships (switching friction, not lock-in)
• ABSENCE: no defensible moat against legislative/regulatory reform; the scale that is the moat is also the political target

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.35 vs analyst floor +0.00 → delta +0.35 (n=19 mgmt / 10 Q&A; 37th pctile across the S&P book, z -0.4).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 1468 articles): avg ticker sentiment +0.14 (bullish 13% / bearish 3%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-10-15 (~52d) — PBM reform legislation / rulemaking outcome (rebate pass-through, transparency) (authored)
• 2027-01-30 (~159d) — FY2026 results + FY2027 EPS guide and MLR outlook (authored)
• 2027-04-01 (~220d) — 2028 Medicare Advantage bid / rate-notice cycle (authored)

Forecast Track Record

• EPS surprise: beat 88% of the last 8 quarters; average surprise +0.7%.
• Prior-forecast backtest (11 snapshots, 2026-06-27→2026-08-20): directional hit-rate 64%; mean predicted -3.5% vs realised -0.9%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

6 catalysts in the next 90 days (of 16 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Consolidated medical care ratio (MCR) > 0.845 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Full-year adjusted EPS guidance < 29.0 (single event). (rationale withheld pending re-authoring — frozen figure or verdict)
• Total revenue growth, year on year < 0.055 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Evernorth Health Services adjusted pre-tax operating income growth, year on year < 0.0 (2 consecutive prints). Evernorth (pharmacy benefit and specialty) carries the earnings mix now that the Medicare Advantage book has been divested. Two prints of contracting Evernorth income would indicate PBM pricing pressure or specialty-drug margin erosion that the base path does not contemplate.
• Federal PBM reform enacted (rebate delinking or spread-pricing ban applying to commercial book) == 1 (single event). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $280; 52-week range $236–$332; engine rating HOLD; house target $273 (-3%). (source: Alpha Vantage 2026-08-24, 25 August 2026)
• INFERENCE: Triangulated FV $266 (-5% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits above the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

56.8/100 (confidence band 45.4–68.2), 43rd percentile of 858 covered names (as of 2026-08-24). Weighted composite under config ros-1.19.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 56.1 → 56.1 → 53.8 → 55.8 → 55.8 → 53.8 → 56.5 → 56.5.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $272.54.

Flagged for review: internal coherence (authored mass vs Monte Carlo). A flag marks a disagreement worth understanding — it does not imply either side is wrong.

Factor Exposures

Cross-sectional percentiles over 858 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.08, vs QQQ -0.01 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Covered Call. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• range-bound with fair premium — harvest income against a holding
• Direction neutral from the overlay conviction/rating (read-only input).
• IV/RV at the 55th percentile of the cross-section → mid vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 71st percentile of its own month-end history (decile 8). The two measures disagree here — vol is high for this name by its own history while its options are not unusually rich against its realised vol. Where they diverge, the cross-sectional measure is the one acting.
• IV term structure is in contango (longer-dated richer, slope +2.9pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.

IV term structure (contango, slope +2.9pp): 32-DTE 31% · 116-DTE 32% · 389-DTE 34%

Economics copied verbatim from the options overlay (priced from the listed chain (EOD marks)); the selector does not re-price.

Alternatives: Cash-Secured Put. IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the HOLD equity view. Chain as of 2026-08-24 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 30.8% (moderate regime) · expected move ±6.4% (2026-09-25) · put/call OI 0.52 · ATM Δ 0.54 / Θ -0.13 / ν 0.33. Direction: NEUTRAL (implied return -5.0% to triangulated fair value $266.41).

Covered Call (if held) (Income / neutral) — Short 300 C · 2026-09-25 · premium $2.08 · yield 0.7% · priced from the listed chain (EOD marks)

Converts a near-fair holding into income by agreeing to sell at a higher strike — worth weighing when upside looks limited near fair value and being called away is acceptable. Illustrative — no outcome is implied or guaranteed.

Put Spread (income) (Income / would-own) — Short 260 P / Long 240 P · 2026-10-02 · net $2.94 · net entry $257.06 · yield 1.1% · RoR 17.0% · max loss $17.06 · priced from the listed chain (EOD marks)

Gets paid to wait for a lower entry, with the tail capped: the sold put collects premium while the cheaper long wing below it caps the maximum loss at the spread width — a defined-risk alternative to a naked cash-secured put.

Protective Collar (if held) (Hedge) — Long 250 P / Short 310 C · 2027-03-19 · net $2.35 · floor -11.0% · cap +11.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -3% vs spot
• Monte Carlo median implies -15% vs spot
• DCF fair value implies -2% vs spot — but this is terminal-value sensitive (exit-multiple $274 vs Gordon $523, 91% apart), so it carries less weight
• Bear case (Structural — Medicare/Medicaid Reform / MLR Squeeze) downside is -57% vs spot
• Net: the valuation anchor itself sits 5.0% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 2% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $38B + PV(terminal) $58B = EV $97B; − net debt $23.9B → equity $73B ÷ diluted shares $0.27B = $274/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $523/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 38% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $1,936 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (569.0); Revenue CAGR ±3pp (87.0); Terminal × ±15% (66.0); WACC ±1pp (28.0); Capex intensity ±15% (15.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 8×, FY+5 revenue $375B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.